Mycoplasma Testing Market, By Product and Services (Kits and Reagents (PCR Assay, Nucleic Acid Detection, Elimination Kits and Reagent, Stains, Standards and Controls, and Other Kits and Reagent), and Instrument), By Technique (PCR, Elisa, Enzymatic Method, and DNA Staining), By End-User (Cell Line Testing, and Virus Testing), By End-User (Pharmaceutical Companies and Cell Banks), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI391820 | Publish Date: April 2024 | No. of Pages: 180

Global Mycoplasma Testing Market By Overview

Mycoplasma testing is carried out to detect the presence of mycoplasma bacterial cells. Mycoplasma bacteria can be found in humans, animals, plants, sewage, or even soil. Cell culture contamination caused due to mycoplasma bacteria alters the results to a great extent; therefore, at every step of the cell culture process, mycoplasma testing is very crucial. Mycoplasma contamination is difficult to see with a microscope and requires specific testing, to be detected. Contamination can have a profound impact on experimental work. Depending on the species present, mycoplasma organisms can affect cell growth, metabolism, tumourigenicity, and response to chemotherapy. Mycoplasma Testing Market accounted for US$ 643.21 million in 2020 and is estimated to be US$ 1504.47 million by 2030 and is anticipated to register a CAGR of 9.0%.

Introduction - Mycoplasma Testing Market

Disclaimer: Data is only a representation. Actual data may vary in the final report.

Global Mycoplasma Testing Market By Drivers & Restraints

Growing cell contamination and increased instances of mycoplasma bacterial

The major factor that drives the global mycoplasma testing market are growing cell contamination and increased instances of mycoplasma bacterial. Mycoplasma testing is an important step in cell culture as mycoplasma infection can lead to changes in the physio-chemical properties of the cell. In addition, hinder cell growth, resulting in inefficient cellular product or unsafe pharmaceutical product. Launch of new product and instruments used for mycoplasma testing is expected to fuel the demand for mycoplasma testing and eventually drive the target market growth.  Introduction of new product enhancing the efficiency and convenience in the diagnosis processes, by the market players is boosting the target market growth of mycoplasma testing. Increased investment in research and development activities coupled with increased government support has led to an expansion in the biopharmaceutical industry, which eventually is expected to increase the mycoplasma testing of target market. Owing to an increased use of cell lines for research and pharmaceutical product, this segment accounts the largest market share and is majorly driving the overall growth of the global mycoplasma testing of target market. However, lack of awareness and difficulty in detection of mycoplasma testing, as most of them are harmless, is expected to hinder the global market growth of mycoplasma testing in the coming years. Additionally, resistance against certain antibiotics such as penicillin, due to absence of cell wall in mycoplasma bacteria, acts as a restraint to the mycoplasma testing global market.

Global Mycoplasma Testing Market By Segmentations & Regional Insights

Mycoplasma testing market is segmented based on Product and Services, technique, application, end-user, and region.

Based on product and services, the mycoplasma testing market is segmented into the kits and reagents and instruments. the kits and reagents is further classified into PCR assay, nucleic acid detection, elimination kits and reagent, stains, standards and controls, and other kits and reagent. Based on the technique, the target market is segmented into PCR, Elisa, enzymatic method, and DNA staining. Based on application, the global market is classified into cell line testing, and virus testing. Based on end-user, the target market is bifurcated into pharmaceutical companies and cell banks.

Regional Insights:

Mycoplasma Testing Market accounted for US$ 643.21 million in 2020 and is estimated to be US$ 1504.47 million by 2030 and is anticipated to register a CAGR of 9.0%. Based on the region the lmycoplasma testing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is expected to hold major share in the market over the forecast tenure. This growth is attributed due to huge investments and increased healthcare expenditure especially in U.S.  In addition, rising government initiatives to promote research based activities in the biopharmaceuticals industries is also expected to boost growth of the target market in this region. Europe is likely to take second position in the global market. On the other hand, Asia Pacific is also expected to stoke up the demand in the mycoplasma testing market in the coming years. Countries such as China, India, and Japan are large number of companies establishing their plants and expanding their business in these regions which in turn is likely to boost Asia Pacific mycoplasma testing market. 

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2029

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Product & Services - Kits and Reagents (PCR Assay, Nucleic Acid Detection, Elimination Kits and Reagent, Stains, Standards and Controls, and Other Kits and Reagent), and Instrument

By Technique - PCR, Elisa, Enzymatic Method, and DNA Staining

By Application - Cell Line Testing, Virus Testing

By End-User – Pharmaceutical Companies and Cell Banks

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

 

 

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the mycoplasma testing market report based on Product & Service, Technique, Application, End-User and Region.

Segmentation - Mycoplasma Testing Market

Mycoplasma Testing Market, By Region:

  • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Mycoplasma Testing Market By Competitive Landscape & Key Players

The key players operating the global mycoplasma testing market Involves Meridian Bioscience, Thermo Fisher Scientific, Lonza Group Ltd., Merck Kgaa, Roche Diagnostics, American Type Culture Collection, Bionique Testing Laboratories, Inc., Invivogen, Promocell Gmbh, Norgen Biotek Corp. prominent players operating in the target market are focusing on launching of the Product to gain a competitive edge in the target market. For instance, in February 2019, Meridian Bioscience, introduced Immunocard mycoplasma, a rapid and sensitive enzyme immunoassay, used for detection of presence of mycoplasma pneumonia in human serum. In addition, in April 2018, Thermo Fisher Scientific launched MycoSEQ mycoplasma detection kit. It is a fully integrated solution for real-time PCR-based mycoplasma detection.

Global Mycoplasma Testing Market By Company Profile

  • Meridian Bioscience
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Thermo Fisher Scientific
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Lonza Group Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck KgaA
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Roche Diagnostics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • American Type Culture Collection
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bionique Testing Laboratories, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Invivogen
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Promocell Gmbh
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Norgen Biotek Corp.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

FAQs

The global mycoplasma testing market is segmented based on Product and Services, technique, application, end-user, and region.

The major factor that drives the global mycoplasma testing market are growing cell contamination and increased instances of mycoplasma bacterial.

The market in North America is expected to hold major share in the market over the forecast tenure. This growth is attributed due to huge investments and increased healthcare expenditure especially in U.S.

The key players operating the global mycoplasma testing market Involves Meridian Bioscience, Thermo Fisher Scientific, Lonza Group Ltd., Merck Kgaa, Roche Diagnostics, American Type Culture Collection, Bionique Testing Laboratories, Inc., Invivogen, Promocell Gmbh, Norgen Biotek Corp.